Merck & Co (NYSE:MRK)‘s stock had its “buy” rating restated by equities research analysts at TheStreet in a research note issued to investors on Friday, StockRatingsNetwork reports.
The analysts wrote, “Merck (MRK) has been reiterated by TheStreet Ratings as a buy with a ratings score of B+. The company’s strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.”
Several other analysts have also recently commented on the stock. Analysts at BMO Capital Markets cut their price target on shares of Merck & Co to $48.00 in a research note to investors on Thursday. They now have a “market perform” rating on the stock. Separately, analysts at Sanford C. Bernstein downgraded shares of Merck & Co from an “outperform” rating to a “market perform” rating in a research note to investors on Monday. They now have a $50.00 price target on the stock, down previously from $53.00. Finally, analysts at Jefferies Group downgraded shares of Merck & Co from a “buy” rating to a “hold” rating in a research note to investors on Friday, October 11th. They now have a $50.00 price target on the stock, down previously from $53.00. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $50.96.
Shares of Merck & Co (NYSE:MRK) traded down 0.79% during mid-day trading on Friday, hitting $46.74. 6,721,680 shares of the company’s stock traded hands. Merck & Co has a one year low of $40.02 and a one year high of $50.16. The stock has a 50-day moving average of $47.70 and a 200-day moving average of $47.35. The company has a market cap of $136.8 billion and a P/E ratio of 28.21.
Merck & Co (NYSE:MRK) last issued its quarterly earnings data on Tuesday, July 30th. The company reported $0.84 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.82 by $0.02. The company had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $11.22 billion. During the same quarter in the prior year, the company posted $1.05 earnings per share. The company’s quarterly revenue was down 10.6% on a year-over-year basis. On average, analysts predict that Merck & Co will post $3.48 earnings per share for the current fiscal year.
Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.